Dendritic cells (DCs) are key regulators of immune responses that operate at the interface between innate and adaptive immunity, and defects in DC functions contribute to the pathogenesis of a variety of disorders. For instance, cancer evolves in the context of limited DC activity, and some autoimmune diseases are initiated by DC-dependent antigen presentation. Thus, correcting aberrant DC functions stands out as a promising therapeutic paradigm for a variety of diseases, as demonstrated by an abundant preclinical and clinical literature accumulating over the past two decades. However, the therapeutic potential of DC-targeting approaches remains to be fully exploited in the clinic. Here, we discuss the unique features of DCs that underlie the high therapeutic potential of DC-targeting strategies and critically analyze the obstacles that have prevented the full realization of this promising paradigm.

Department of Immunology 2nd Faculty of Medicine and University Hospital Motol Charles University Prague Czechia

Sotio Prague Czechia

Zobrazit více v PubMed

Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. (2001) 106:259–62. 10.1016/S0092-8674(01)00456-1 PubMed DOI

Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. (2010) 234:45–54. 10.1111/j.0105-2896.2009.00879.x PubMed DOI

Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. (2005) 23:275–306. 10.1146/annurev.immunol.23.021704.115633 PubMed DOI

Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. (1973) 137:1142–62. 10.1084/jem.137.5.1142 PubMed DOI PMC

Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, et al. . Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. (2010) 59:1573–82. 10.1007/s00262-010-0833-1 PubMed DOI PMC

Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood. (2012) 120:3936–44. 10.1182/blood-2012-06-435941 PubMed DOI

Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. (2019). [Epub ahead of print]. 10.1038/s41577-019-0210-z PubMed DOI

Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. (2013) 31:563–604. 10.1146/annurev-immunol-020711-074950 PubMed DOI PMC

Audiger C, Rahman MJ, Yun TJ, Tarbell KV, Lesage S. The importance of dendritic cells in maintaining immune tolerance. J Immunol. (2017) 198:2223–31. 10.4049/jimmunol.1601629 PubMed DOI PMC

Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. (2012) 30:1–22. 10.1146/annurev-immunol-100311-102839 PubMed DOI

Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. (2018) 154:3–20. 10.1111/imm.12888 PubMed DOI PMC

Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. (2017) 27:74–95. 10.1038/cr.2016.157 PubMed DOI PMC

Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res. (2016) 22:1897–906. 10.1158/1078-0432.CCR-15-1399 PubMed DOI

Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. (2014) 15:e257–67. 10.1016/S1470-2045(13)70585-0 PubMed DOI

Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. (2013) 39:38–48. 10.1016/j.immuni.2013.07.004 PubMed DOI PMC

Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. (2014) 40:642–56. 10.1016/j.immuni.2014.04.016 PubMed DOI

Shaw J, Wang YH, Ito T, Arima K, Liu YJ. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood. (2010) 115:3051–7. 10.1182/blood-2009-08-239145 PubMed DOI PMC

Schlitzer A, McGovern N, Ginhoux F. Dendritic cells and monocyte-derived cells: two complementary and integrated functional systems. Semin Cell Dev Biol. (2015) 41:9–22. 10.1016/j.semcdb.2015.03.011 PubMed DOI

Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man. Front Immunol. (2015) 6:569. 10.3389/fimmu.2015.00569 PubMed DOI PMC

Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol. (2013) 4:438. 10.3389/fimmu.2013.00438 PubMed DOI PMC

Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, et al. . Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol Rev. (2015) 67:731–53. 10.1124/pr.114.009456 PubMed DOI

Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. . Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. (2013) 73:1063–75. 10.1158/0008-5472.CAN-12-2583 PubMed DOI

Sittig SP, Bakdash G, Weiden J, Skold AE, Tel J, Figdor CG, et al. . A comparative study of the T cell stimulatory and polarizing capacity of human primary blood dendritic cell subsets. Mediators Inflammation. (2016) 2016:3605643. 10.1155/2016/3605643 PubMed DOI PMC

Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med. (2013) 210:1035–47. 10.1084/jem.20121103 PubMed DOI PMC

Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. . IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity. (2013) 38:970–83. 10.1016/j.immuni.2013.04.011 PubMed DOI PMC

Williams JW, Tjota MY, Clay BS, Vander Lugt B, Bandukwala HS, Hrusch CL, et al. . Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun. (2013) 4:2990. 10.1038/ncomms3990 PubMed DOI PMC

Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. . Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity. (2013) 38:336–48. 10.1016/j.immuni.2012.10.018 PubMed DOI

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. . Immunobiology of dendritic cells. Annu Rev Immunol. (2000) 18:767–811. 10.1146/annurev.immunol.18.1.767 PubMed DOI

Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. (2019) 19:89–103. 10.1038/s41577-018-0088-1 PubMed DOI PMC

Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. (2002) 23:445–9. 10.1016/S1471-4906(02)02281-0 PubMed DOI

Tai Y, Wang Q, Korner H, Zhang L, Wei W. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. (2018) 9:642. 10.3389/fphar.2018.00642 PubMed DOI PMC

Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, et al. . Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest. (2013) 123:844–54. 10.1172/JCI65260 PubMed DOI PMC

Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. (2001) 19:47–64. 10.1146/annurev.immunol.19.1.47 PubMed DOI

Soto-Nieves N, Puga I, Abe BT, Bandyopadhyay S, Baine I, Rao A, et al. . Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance. J Exp Med. (2009) 206:867–76. 10.1084/jem.20082731 PubMed DOI PMC

Osorio F, Fuentes C, Lopez MN, Salazar-Onfray F, Gonzalez FE. Role of dendritic cells in the induction of lymphocyte tolerance. Front Immunol. (2015) 6:535. 10.3389/fimmu.2015.00535 PubMed DOI PMC

Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood. (2011) 117:3096–103. 10.1182/blood-2010-08-301275 PubMed DOI PMC

Horton C, Shanmugarajah K, Fairchild PJ. Harnessing the properties of dendritic cells in the pursuit of immunological tolerance. Biomed J. (2017) 40:80–93. 10.1016/j.bj.2017.01.002 PubMed DOI PMC

Sanchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Perez-Gracia JL, Sanchez-Arraez A, et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. (2017) 28:xii74 10.1093/annonc/mdx727 PubMed DOI

Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et al. . ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. (2015) 161:1527–38. 10.1016/j.cell.2015.05.025 PubMed DOI PMC

Mancino A, Schioppa T, Larghi P, Pasqualini F, Nebuloni M, Chen IH, et al. . Divergent effects of hypoxia on dendritic cell functions. Blood. (2008) 112:3723–34. 10.1182/blood-2008-02-142091 PubMed DOI

Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. (2015) 523:231–5. 10.1038/nature14404 PubMed DOI

Paardekooper LM, Vos W, van den Bogaart G. Oxygen in the tumor microenvironment: effects on dendritic cell function. Oncotarget. (2019) 10:883–96. 10.18632/oncotarget.26608 PubMed DOI PMC

Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. (2010) 108:111–65. 10.1016/B978-0-12-380995-7.00004-5 PubMed DOI PMC

Adnan E, Matsumoto T, Ishizaki J, Onishi S, Suemori K, Yasukawa M, et al. . Human tolerogenic dendritic cells generated with protein kinase C inhibitor are optimal for functional regulatory T cell induction - A comparative study. Clin Immunol. (2016) 173:96–108. 10.1016/j.clim.2016.09.007 PubMed DOI

Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunology. (2012) 3:233. 10.3389/fimmu.2012.00233 PubMed DOI PMC

Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci. (2011) 1:20. 10.1186/2045-3701-1-20 PubMed DOI PMC

Ferreira GB, Vanherwegen AS, Eelen G, Gutierrez ACF, Van Lommel L, Marchal K, et al. . Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways. Cell Rep. (2015) 10:711–25. 10.1016/j.celrep.2015.01.013 PubMed DOI

Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. (2014) 27:16–25. 10.1016/j.coi.2014.01.004 PubMed DOI PMC

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. 10.1016/j.cell.2011.02.013 PubMed DOI

Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer. (2013) 4:36–44. 10.7150/jca.5046 PubMed DOI PMC

Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martinez-Cano S, et al. . Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8(+) T cells. Nat Commun. (2017) 8:16073. 10.1038/ncomms16073 PubMed DOI PMC

Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. (2012) 12:557–69. 10.1038/nri3254 PubMed DOI

Bottcher JP, Reis ESC. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. (2018) 4:784–92. 10.1016/j.trecan.2018.09.001 PubMed DOI PMC

Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. . Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. (2010) 207:1247–60. 10.1084/jem.20092140 PubMed DOI PMC

Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, et al. . Cancer immunotherapy with immunomodulatory anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. (2016) 6:71–9. 10.1158/2159-8290.CD-15-0510 PubMed DOI PMC

Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, et al. . Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity. Cell. (2019) 177:556–71 e16. 10.1016/j.cell.2019.02.005 PubMed DOI PMC

Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, et al. . Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood. (2013) 122:932–42. 10.1182/blood-2013-04-495424 PubMed DOI

Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. . Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. (2014) 74:705–15. 10.1158/0008-5472.CAN-13-1342 PubMed DOI

Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al. . Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. (2018) 6:139. 10.1186/s40425-018-0446-3 PubMed DOI PMC

Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. . Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. (2007) 56:1459–69. 10.1007/s00262-007-0286-3 PubMed DOI PMC

Giraldo NA, Becht E, Pages F, Skliris G, Verkarre V, Vano Y, et al. . Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. (2015) 21:3031–40. 10.1158/1078-0432.CCR-14-2926 PubMed DOI

Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard JP. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer. J Immunol. (2013) 191:2001–8. 10.4049/jimmunol.1300872 PubMed DOI

Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, et al. . Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. (2013) 19:4079–91. 10.1158/1078-0432.CCR-12-3847 PubMed DOI

Morello S, Pinto A, Blandizzi C, Antonioli L. Myeloid cells in the tumor microenvironment: role of adenosine. Oncoimmunology. (2016) 5:e1108515. 10.1080/2162402X.2015.1108515 PubMed DOI PMC

Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, et al. . Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. (2012) 21:402–17. 10.1016/j.ccr.2012.01.008 PubMed DOI PMC

Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. . Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. (2012) 13:832–42. 10.1038/ni.2376 PubMed DOI PMC

Garg AD, Romano E, Rufo N, Agostinis P. Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Different. (2016) 23:938–51. 10.1038/cdd.2016.5 PubMed DOI PMC

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. (2017) 17:97–111. 10.1038/nri.2016.107 PubMed DOI

Segawa K, Nagata S. An apoptotic ‘eat me' signal: phosphatidylserine exposure. Trends Cell Biol. (2015) 25:639–50. 10.1016/j.tcb.2015.08.003 PubMed DOI

Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. . Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. (2010) 2:63ra94. 10.1126/scitranslmed.3001375 PubMed DOI PMC

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, et al. . Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. (2015) 6:588. 10.3389/fimmu.2015.00588 PubMed DOI PMC

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. . Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. (2005) 11:1314–21. 10.1038/nm1325 PubMed DOI

Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. . Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. (2005) 202:919–29. 10.1084/jem.20050463 PubMed DOI PMC

Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, et al. . Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med. (2007) 204:1037–47. 10.1084/jem.20061120 PubMed DOI PMC

Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. (2006) 25:333–56. 10.1007/s10555-006-9010-6 PubMed DOI

Tourkova IL, Shurin GV, Wei S, Shurin MR. Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol. (2007) 178:7787–93. 10.4049/jimmunol.178.12.7787 PubMed DOI

Bennaceur K, Chapman JA, Touraine JL, Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta. (2009) 1795:16–24. 10.1016/j.bbcan.2008.07.001 PubMed DOI

Ting YT, Petersen J, Ramarathinam SH, Scally SW, Loh KL, Thomas R, et al. . The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J Biol Chem. (2018) 293:3236–51. 10.1074/jbc.RA117.001013 PubMed DOI PMC

Amodio G, Gregori S. Human tolerogenic DC-10: perspectives for clinical applications. Transpl Res. (2012) 1:14. 10.1186/2047-1440-1-14 PubMed DOI PMC

Mackern-Oberti JP, Llanos C, Riedel CA, Bueno SM, Kalergis AM. Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus. Immunology. (2015) 146:497–507. 10.1111/imm.12504 PubMed DOI PMC

Wehr P, Purvis H, Law SC, Thomas R. Dendritic cells, T cells and their interaction in rheumatoid arthritis. Clin Exp Immunol. (2019) 196:12–27. 10.1111/cei.13256 PubMed DOI PMC

Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, et al. . Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. (2011) 106:1544–55. 10.1038/ajg.2011.112 PubMed DOI

Green DR, Oguin TH, Martinez J. The clearance of dying cells: table for two. Cell Death Different. (2016) 23:915–26. 10.1038/cdd.2015.172 PubMed DOI PMC

Abdolmaleki F, Farahani N, Gheibi Hayat SM, Pirro M, Bianconi V, Barreto GE, et al. . The role of efferocytosis in autoimmune diseases. Front Immunol. (2018) 9:1645. 10.3389/fimmu.2018.01645 PubMed DOI PMC

Zaiss DM, Bekker CP, Grone A, Lie BA, Sijts AJ. Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol. (2011) 187:2302–9. 10.4049/jimmunol.1101003 PubMed DOI PMC

Arleevskaya MI, Kravtsova OA, Lemerle J, Renaudineau Y, Tsibulkin AP. How rheumatoid arthritis can result from provocation of the immune system by microorganisms and viruses. Front Microbiol. (2016) 7:1296. 10.3389/fmicb.2016.01296 PubMed DOI PMC

Sozzani S, Del Prete A, Bosisio D. Dendritic cell recruitment and activation in autoimmunity. J Autoimmun. (2017) 85:126–40. 10.1016/j.jaut.2017.07.012 PubMed DOI

Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, et al. . Increased IFN-alpha-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-alpha production. J Immunol. (2014) 193:1024–34. 10.4049/jimmunol.1303230 PubMed DOI PMC

Speck-Hernandez CA, Montoya-Ortiz G. Silicon, a possible link between environmental exposure and autoimmune diseases: the case of rheumatoid arthritis. Arthritis. (2012) 2012:604187. 10.1155/2012/604187 PubMed DOI PMC

Abeler-Dorner L, Rieger CC, Berger B, Weyd H, Graf D, Pfrang S, et al. . Interferon-alpha abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis. J Rheumatol. (2013) 40:1683–96. 10.3899/jrheum.121299 PubMed DOI

Gallo PM, Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol. (2013) 4:138. 10.3389/fimmu.2013.00138 PubMed DOI PMC

Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. . Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. (2011) 3:73ra19. 10.1126/scitranslmed.3001180 PubMed DOI PMC

Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. . Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. (2011) 3:73ra20. 10.1126/scitranslmed.3001201 PubMed DOI PMC

Gkirtzimanaki K, Kabrani E, Nikoleri D, Polyzos A, Blanas A, Sidiropoulos P, et al. . IFNalpha impairs autophagic degradation of mtdna promoting autoreactivity of SLE monocytes in a STING-dependent fashion. Cell Rep. (2018) 25:921–33.e5. 10.1016/j.celrep.2018.09.001 PubMed DOI PMC

Beaudoin L, Diana J, Ghazarian L, Simoni Y, Boitard C, Lehuen A. Plasmacytoid dendritic cells license regulatory T cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes. Eur J Immunol. (2014) 44:1454–66. 10.1002/eji.201343910 PubMed DOI

Lippens C, Duraes FV, Dubrot J, Brighouse D, Lacroix M, Irla M, et al. . IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J Autoimmun. (2016) 75:39–49. 10.1016/j.jaut.2016.07.004 PubMed DOI PMC

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. (2012) 12:265–77. 10.1038/nrc3258 PubMed DOI PMC

Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. (1994) 179:1109–18. 10.1084/jem.179.4.1109 PubMed DOI PMC

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. . Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. (1996) 2:52–8. 10.1038/nm0196-52 PubMed DOI

Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, et al. . Trial watch: dendritic cell-based anticancer immunotherapy. Oncoimmunology. (2017) 6:e1328341. 10.1080/2162402X.2017.1328341 PubMed DOI PMC

Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. . Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. (2013) 62:137–47. 10.1007/s00262-012-1317-2 PubMed DOI PMC

Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. . Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. (2011) 29:330–6. 10.1200/JCO.2010.30.7744 PubMed DOI PMC

Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, et al. . IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest. (2013) 123:3383–94. 10.1172/JCI68395 PubMed DOI PMC

Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, et al. . Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. (2012) 35:641–9. 10.1097/CJI.0b013e31826f79c8 PubMed DOI

Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. . Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep. (2012) 28:1131–8. 10.3892/or.2012.1956 PubMed DOI PMC

Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, et al. . Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{α}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. (2009) 15:4986–92. 10.1158/1078-0432.CCR-08-3240 PubMed DOI PMC

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. (2010) 363:411–22. 10.1056/NEJMoa1001294 PubMed DOI

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. (2018) 16:142 10.1186/s12967-018-1507-6 PubMed DOI PMC

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. (2015) 348:803–8. 10.1126/science.aaa3828 PubMed DOI PMC

Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, et al. . Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood. (2010) 116:1685–97. 10.1182/blood-2010-01-264960 PubMed DOI PMC

Meyer-Wentrup F, Cambi A, Joosten B, Looman MW, de Vries IJ, Figdor CG, et al. . DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukocyte Biol. (2009) 85:518–25. 10.1189/jlb.0608352 PubMed DOI

Ni L, Gayet I, Zurawski S, Duluc D, Flamar AL, Li XH, et al. . Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses. J Immunol. (2010) 185:3504–13. 10.4049/jimmunol.1000999 PubMed DOI PMC

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. . Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. (2014) 6:232ra51. 10.1126/scitranslmed.3008068 PubMed DOI PMC

Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. (2010) 16:304–10. 10.1097/PPO.0b013e3181eb33d7 PubMed DOI PMC

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, et al. . Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. (2004) 200:297–306. 10.1084/jem.20031435 PubMed DOI PMC

Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. . A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. (2011) 253:328–35. 10.1097/SLA.0b013e3181fd271c PubMed DOI PMC

Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol. (2009) 5:187–96. 10.2217/14796694.5.2.187 PubMed DOI PMC

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. . Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. (2016) 44:924–38. 10.1016/j.immuni.2016.03.012 PubMed DOI PMC

Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. (2011) 34:2026–32. 10.2337/dc11-0472 PubMed DOI PMC

Phillips BE, Garciafigueroa Y, Trucco M, Giannoukakis N. Clinical tolerogenic dendritic cells: exploring therapeutic impact on human autoimmune disease. Front Immunol. (2017) 8:1279. 10.3389/fimmu.2017.01279 PubMed DOI PMC

De Laere M, Derdelinckx J, Hassi M, Kerosalo M, Oravamaki H, Van den Bergh J, et al. . Shuttling tolerogenic dendritic cells across the blood-brain barrier in vitro via the introduction of de novo C-C chemokine receptor 5 expression using messenger RNA electroporation. Front Immunol. (2017) 8:1964. 10.3389/fimmu.2017.01964 PubMed DOI PMC

Danova K, Grohova A, Strnadova P, Funda DP, Sumnik Z, Lebl J, et al. . Tolerogenic dendritic cells from poorly compensated type 1 diabetes patients have decreased ability to induce stable antigen-specific T cell hyporesponsiveness and generation of suppressive regulatory T cells. J Immunol. (2017) 198:729–40. 10.4049/jimmunol.1600676 PubMed DOI

Grohova A, Danova K, Spisek R, Palova-Jelinkova L. Cell based therapy for type 1 diabetes: should we take hyperglycemia into account? Front Immunol. (2019) 10:79. 10.3389/fimmu.2019.00079 PubMed DOI PMC

Mansilla MJ, Contreras-Cardone R, Navarro-Barriuso J, Cools N, Berneman Z, Ramo-Tello C, et al. . Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. J Neuroinflammation. (2016) 13:113. 10.1186/s12974-016-0584-9 PubMed DOI PMC

Funda DP, Golias J, Hudcovic T, Kozakova H, Spisek R, Palova-Jelinkova L. Antigen loading (e.g., glutamic acid decarboxylase 65) of tolerogenic DCs (tolDCs) reduces their capacity to prevent diabetes in the non-obese diabetes (NOD)-severe combined immunodeficiency model of adoptive cotransfer of diabetes as well as in NOD mice. Front Immunol. (2018) 9:290. 10.3389/fimmu.2018.00290 PubMed DOI PMC

Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol. (2004) 173:4331–41. 10.4049/jimmunol.173.7.4331 PubMed DOI

Engmann O, Giralt A, Gervasi N, Marion-Poll L, Gasmi L, Filhol O, et al. . DARPP-32 interaction with adducin may mediate rapid environmental effects on striatal neurons. Nat Commun. (2015) 6:10099. 10.1038/ncomms10099 PubMed DOI PMC

Riedhammer C, Weissert R. Antigen presentation, autoantigens, and immune regulation in multiple sclerosis and other autoimmune diseases. Front Immunol. (2015) 6:322. 10.3389/fimmu.2015.00322 PubMed DOI PMC

Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med. (2012) 2:a007781. 10.1101/cshperspect.a007781 PubMed DOI PMC

Jansen MAA, Spiering R, Broere F, van Laar JM, Isaacs JD, van Eden W, et al. . Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases? Immunology. (2018) 153:51–9. 10.1111/imm.12811 PubMed DOI PMC

Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol. (2017) 8:1764. 10.3389/fimmu.2017.01764 PubMed DOI PMC

Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, et al. . LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukocyte Biol. (2009) 85:243–50. 10.1189/jlb.0608374 PubMed DOI PMC

Hasegawa H, Matsumoto T. Mechanisms of tolerance induction by dendritic cells in vivo. Front Immunol. (2018) 9:350. 10.3389/fimmu.2018.00350 PubMed DOI PMC

Giannoukakis N, Trucco M. A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. (2012) 19:279–87. 10.1097/MED.0b013e328355461b PubMed DOI

Ten Brinke A, Martinez-Llordella M, Cools N, Hilkens CMU, van Ham SM, Sawitzki B, et al. . Ways forward for tolerance-inducing cellular therapies- an AFACTT perspective. Front Immunol. (2019) 10:181. 10.3389/fimmu.2019.00181 PubMed DOI PMC

Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, et al. . Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. (2015) 7:290ra87. 10.1126/scitranslmed.aaa9301 PubMed DOI

Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, et al. . Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. (2017) 76:227–34. 10.1136/annrheumdis-2015-208456 PubMed DOI PMC

Jauregui-Amezaga A, Cabezon R, Ramirez-Morros A, Espana C, Rimola J, Bru C, et al. . Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn's disease: a phase I study. J Crohn's Colitis. (2015) 9:1071–8. 10.1093/ecco-jcc/jjv144 PubMed DOI

Zubizarreta I, Florez-Grau G, Vila G, Cabezon R, Espana C, Andorra M, et al. . Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc Natl Acad Sci USA. (2019) 116:8463–70. 10.1073/pnas.1820039116 PubMed DOI PMC

Florez-Grau G, Zubizarreta I, Cabezon R, Villoslada P, Benitez-Ribas D. Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials. Front Immunol. (2018) 9:1169. 10.3389/fimmu.2018.01169 PubMed DOI PMC

Tabansky I, Keskin DB, Watts D, Petzold C, Funaro M, Sands W, et al. . Targeting DEC-205(-)DCIR2(+) dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis. Mol Med. (2018) 24:17. 10.1186/s10020-018-0017-6 PubMed DOI PMC

LaMothe RA, Kolte PN, Vo T, Ferrari JD, Gelsinger TC, Wong J, et al. . Tolerogenic nanoparticles induce antigen-specific regulatory T cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis. Front Immunol. (2018) 9:281. 10.3389/fimmu.2018.00281 PubMed DOI PMC

Saas P, Daguindau E, Perruche S. Concise review: apoptotic cell-based therapies-rationale, preclinical results and future clinical developments. Stem Cells. (2016) 34:1464–73. 10.1002/stem.2361 PubMed DOI

Pishesha N, Bilate AM, Wibowo MC, Huang NJ, Li Z, Deshycka R, et al. . Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci USA. (2017) 114:3157–62. 10.1073/pnas.1705149114 PubMed DOI PMC

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. (2018) 10:eaat7807. 10.1126/scitranslmed.aat7807 PubMed DOI

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, et al. . Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. (2014) 3:e27878. 10.4161/onci.27878 PubMed DOI PMC

Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. (2006) 90:1–50. 10.1016/S0065-2776(06)90001-7 PubMed DOI

Vacchelli E, Bloy N, Aranda F, Buque A, Cremer I, Demaria S, et al. . Trial watch: immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. (2016) 5:e1214790. 10.1080/2162402X.2016.1214790 PubMed DOI PMC

Truxova I, Hensler M, Skapa P, Halaska MJ, Laco J, Ryska A, et al. . Rationale for the combination of dendritic cell-based vaccination approaches with chemotherapy agents. Int Rev Cell Mol Biol. (2017) 330:115–56. 10.1016/bs.ircmb.2016.09.003 PubMed DOI

Hanoteau A, Moser M. Chemotherapy and immunotherapy: a close interplay to fight cancer? Oncoimmunology. (2016) 5:e1190061. 10.1080/2162402X.2016.1190061 PubMed DOI PMC

Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. (2013) 62:203–16. 10.1007/s00262-012-1388-0 PubMed DOI PMC

Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, et al. . Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med. (2011) 9:223. 10.1186/1479-5876-9-223 PubMed DOI PMC

Truxova I, Pokorna K, Kloudova K, Partlova S, Spisek R, Fucikova J. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. Immunol Lett. (2014) 160:39–49. 10.1016/j.imlet.2014.03.010 PubMed DOI

Hradilova N, Sadilkova L, Palata O, Mysikova D, Mrazkova H, Lischke R, et al. . Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS ONE. (2017) 12:e0171539. 10.1371/journal.pone.0171539 PubMed DOI PMC

Kloudova K, Hromadkova H, Partlova S, Brtnicky T, Rob L, Bartunkova J, et al. . Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. Oncotarget. (2016) 7:46120–6. 10.18632/oncotarget.10028 PubMed DOI PMC

Urbanova L, Hradilova N, Moserova I, Vosahlikova S, Sadilkova L, Hensler M, et al. . High hydrostatic pressure affects antigenic pool in tumor cells: implication for dendritic cell-based cancer immunotherapy. Immunol Lett. (2017) 187:27–34. 10.1016/j.imlet.2017.05.005 PubMed DOI

Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. (2014) 3:e968434. 10.4161/21624011.2014.968434 PubMed DOI PMC

Adkins I, Hradilova N, Palata O, Sadilkova L, Palova-Jelinkova L, Spisek R. High hydrostatic pressure in cancer immunotherapy and biomedicine. Biotechnol Adv. (2018) 36:577–82. 10.1016/j.biotechadv.2018.01.015 PubMed DOI

Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, et al. . High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. (2014) 135:1165–77. 10.1002/ijc.28766 PubMed DOI

Mikyskova R, Indrova M, Stepanek I, Kanchev I, Bieblova J, Vosahlikova S, et al. . Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. Oncoimmunology. (2017) 6:e1362528. 10.1080/2162402X.2017.1362528 PubMed DOI PMC

Mikyskova R, Stepanek I, Indrova M, Bieblova J, Simova J, Truxova I, et al. . Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol. (2016) 48:953–64. 10.3892/ijo.2015.3314 PubMed DOI PMC

Moserova I, Truxova I, Garg AD, Tomala J, Agostinis P, Cartron PF, et al. . Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. Oncoimmunology. (2017) 6:e1258505. 10.1080/2162402X.2016.1258505 PubMed DOI PMC

Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, et al. Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. Cancer Immunol Immunother. (2018) 67:89–100. 10.1007/s00262-017-2068-x PubMed DOI PMC

Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, et al. . Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. (2015) 6:18192–205. 10.18632/oncotarget.4145 PubMed DOI PMC

Hayashi T, Yao S, Crain B, Promessi VJ, Shyu L, Sheng C, et al. . Induction of tolerogenic dendritic cells by a PEGylated TLR7 ligand for treatment of type 1 diabetes. PLoS ONE. (2015) 10:e0129867. 10.1371/journal.pone.0129867 PubMed DOI PMC

Danova K, Klapetkova A, Kayserova J, Sediva A, Spisek R, Jelinkova LP. NF-kappaB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget. (2015) 6:14123–38. 10.18632/oncotarget.4234 PubMed DOI PMC

Impaired Proliferation of CD8+ T Cells Stimulated with Monocyte-Derived Dendritic Cells Previously Matured with Thapsigargin-Stimulated LAD2 Human Mast Cells

Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines

Immunological configuration of ovarian carcinoma: features and impact on disease outcome